Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732074 | 0.83 | TSHR (0.59) | NTRK1KCNJ6KCNJ5KCNJ3TSHR | |
| SCHEMBL27676108 | 0.83 | SOAT2 (0.52) | RAB9ATSHRCTSKKDM4ESMN1; SMN2 | |
| SCHEMBL22828238 | 0.80 | RAB9A (0.46) | RAB9AMAPTKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL23719149 | 0.79 | MAPK10 (0.51) | RAB9AMAPTMAPK13MAPK12MAPK11 | |
| SCHEMBL9453146 | 0.79 | SOAT1 (0.58) | RAB9ATSHRCTSKKDM4ESMN1; SMN2 | |
| SCHEMBL11086699 | 0.78 | SOAT1 (0.60) | RAB9ATSHRCTSKKDM4ESMN1; SMN2 | |
| SCHEMBL2943942 | 0.75 | MEN1 (0.60) | RAB9AMAPTKMT2AMAPK14SMN1; SMN2 | |
| SCHEMBL23719191 | 0.75 | MAPT (0.54) | RAB9AMAPTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL23719173 | 0.74 | CPB1 (0.43) | RAB9AMAPTKMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL3433504 | 0.74 | CYP2C9 (0.55) | NTRK1KCNJ6KCNJ5KCNJ3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RAB9A 876/4885MAPT 3027/4885NTRK1 4073/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | RAB9A 1457/4885MAPT 3503/4885NTRK1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.